135 related articles for article (PubMed ID: 36739734)
1. Remodeling liver microenvironment by L-arginine loaded hollow polydopamine nanoparticles for liver cirrhosis treatment.
Wang Y; Liu Y; Liu Y; Zhong J; Wang J; Sun L; Yu L; Wang Y; Li Q; Jin W; Yan Z
Biomaterials; 2023 Apr; 295():122028. PubMed ID: 36739734
[TBL] [Abstract][Full Text] [Related]
2. Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Antifibrotic and Anti-inflammatory Activities.
Zhang J; Shen H; Xu J; Liu L; Tan J; Li M; Xu N; Luo S; Wang J; Yang F; Tang J; Li Q; Wang Y; Yu L; Yan Z
ACS Nano; 2020 May; 14(5):6305-6322. PubMed ID: 32378877
[TBL] [Abstract][Full Text] [Related]
3. Engineered liposomes targeting hepatic stellate cells overcome pathological barriers and reverse liver fibrosis.
Wang K; Chen H; Zheng J; Chen J; Chen Y; Yuan Y
J Control Release; 2024 Apr; 368():219-232. PubMed ID: 38367862
[TBL] [Abstract][Full Text] [Related]
4. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology and a Rational Basis of Therapy.
Gracia-Sancho J; Maeso-Díaz R; Bosch J
Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
[TBL] [Abstract][Full Text] [Related]
6. The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension.
Duong HT; Dong Z; Su L; Boyer C; George J; Davis TP; Wang J
Small; 2015 May; 11(19):2291-304. PubMed ID: 25641921
[TBL] [Abstract][Full Text] [Related]
7. Relaxin in hepatic fibrosis: What is known and where to head?
Ezhilarasan D
Biochimie; 2021 Aug; 187():144-151. PubMed ID: 34102254
[TBL] [Abstract][Full Text] [Related]
8. pPB Peptide-Mediated siRNA-Loaded Stable Nucleic Acid Lipid Nanoparticles on Targeting Therapy of Hepatic Fibrosis.
Jia Z; Gong Y; Pi Y; Liu X; Gao L; Kang L; Wang J; Yang F; Tang J; Lu W; Li Q; Zhang W; Yan Z; Yu L
Mol Pharm; 2018 Jan; 15(1):53-62. PubMed ID: 29148802
[TBL] [Abstract][Full Text] [Related]
9. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo.
Li Q; Ding Y; Guo X; Luo S; Zhuang H; Zhou J; Xu N; Yan Z
J Cell Mol Med; 2019 Mar; 23(3):1951-1962. PubMed ID: 30592139
[TBL] [Abstract][Full Text] [Related]
10. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
[TBL] [Abstract][Full Text] [Related]
11. Remodeling the hepatic fibrotic microenvironment with emerging nanotherapeutics: a comprehensive review.
Zhao X; Amevor FK; Xue X; Wang C; Cui Z; Dai S; Peng C; Li Y
J Nanobiotechnology; 2023 Apr; 21(1):121. PubMed ID: 37029392
[TBL] [Abstract][Full Text] [Related]
12. Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.
Zhou L; Liang Q; Li Y; Cao Y; Li J; Yang J; Liu J; Bi J; Liu Y
Acta Biomater; 2022 Oct; 152():235-254. PubMed ID: 36087869
[TBL] [Abstract][Full Text] [Related]
13. The antifibrotic potential of a sustained release formulation of a PDGFβ-receptor targeted rho kinase inhibitor.
van Dijk F; Teekamp N; Post E; Schuppan D; Kim YO; Zuidema J; Steendam R; Klose MHM; Meier-Menches SM; Casini A; Horvatovich PL; Sijbrandi NJ; Frijlink HW; Hinrichs WLJ; Poelstra K; Beljaars L; Olinga P
J Control Release; 2019 Feb; 296():250-257. PubMed ID: 30682444
[TBL] [Abstract][Full Text] [Related]
14. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
15. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
[TBL] [Abstract][Full Text] [Related]
16. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.
Hassan R; Tammam SN; Safy SE; Abdel-Halim M; Asimakopoulou A; Weiskirchen R; Mansour S
Eur J Pharm Biopharm; 2019 Jan; 134():96-106. PubMed ID: 30471341
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
Tripathi DM; Vilaseca M; Lafoz E; Garcia-Calderó H; Viegas Haute G; Fernández-Iglesias A; Rodrigues de Oliveira J; García-Pagán JC; Bosch J; Gracia-Sancho J
Gastroenterology; 2018 Nov; 155(5):1564-1577. PubMed ID: 30055171
[TBL] [Abstract][Full Text] [Related]
18. Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis.
Ling L; Li G; Wang G; Meng D; Li Z; Zhang C
Mol Med Rep; 2019 Aug; 20(2):1605-1612. PubMed ID: 31257490
[TBL] [Abstract][Full Text] [Related]
19. Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.
Wang H; Chen XP; Qiu FZ
Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):391-6. PubMed ID: 14599946
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
